
Opinion|Videos|June 16, 2025
Top-Line Results of the Phase 3 ZIRCON Study
Panelists discuss how the ZIRCON trial results showed impressive test characteristics with 95% positive predictive value for clear cell renal cell carcinoma, meaning a positive test strongly indicates cancer requiring treatment.
Advertisement
Episodes in this series

Diagnostic Performance of the ZIRCON Trial
Main Discussion Topics:
- A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC)
- A 75% negative predictive value
- Important observation that non–clear cell positive cases were still malignant
- A positive test indicates cancer with high probability.
Key Points for Physicians:
- When the test is positive, there is a greater than 90% probability of ccRCC.
- The 7% of positive tests that weren’t ccRCC were still malignant tumors.
- A positive test strongly supports proceeding with intervention.
- A simplified interpretation: If it lights up, it’s very likely cancer.
Notable Insights:
A key clinical value is that a positive test is highly reliable for indicating malignancy, even in the small percentage that aren’t specifically ccRCC.
Clinical Significance:
The high positive predictive value provides actionable information that can guide clinical decision-making toward appropriate intervention.
Advertisement
Related to this article

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.

Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement

